Literature DB >> 26358586

Consensus Sequence of 27 African Horse Sickness Virus Genomes from Viruses Collected over a 76-Year Period (1933 to 2009).

A Christiaan Potgieter1, Isabella M Wright2, Alberdina A van Dijk3.   

Abstract

We announce the complete consensus genome sequence of 27 African horse sickness viruses, representing all nine African horse sickness virus (AHSV) serotypes from historical and recent isolates collected over a 76-year period (1933 to 2009). The data set includes the sequence of the virulent Office International des Epizooties AHSV reference strains which are not adapted to cell culture.
Copyright © 2015 Potgieter et al.

Entities:  

Year:  2015        PMID: 26358586      PMCID: PMC4566168          DOI: 10.1128/genomeA.00921-15

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

African horse sickness (AHS) was first identified as a disease in horses in South Africa in 1891 and the viral nature of its etiological agent, African horse sickness virus (AHSV), was established in 1900 (1). The virus is transmitted by hematophagous Culicoides midges (2, 3) and can cause mortalities in up to 95% of fully susceptible horses. AHS is endemic in most of sub-Saharan Africa, occurs sporadically in North Africa, Mediterranean countries, and the Middle East, and a few outbreaks have been recorded in India and Pakistan. AHSV is a double-stranded RNA (dsRNA) virus with ten genome segments that belongs to the genus Orbivirus, family Reoviridae. Nine serotypes of the virus have been distinguished (4, 5). Currently, the AHSV reference strains of the Office International des Epizooties (OIE) used at the ARC-Onderstepoort Veterinary Institute (OVI), South Africa, consist of at least one pathogenic isolate of each serotype from AHS outbreaks between 1955 and 1963 (6). These virulent reference viruses are used as challenge viruses during vaccine trials. Tissue culture–adapted progeny of these viruses and guinea pig sera raised against them are widely used as diagnostic reagents for serotyping AHSV isolates and to determine the immunity status of horses before and after vaccination (6). The histories of the viruses used in this study (Table 1) were compiled from ARC-OVI specimen collection records from 1958 to 2009, records of vaccine trials in horses, personal communication with B. J. Erasmus, and the literature (4, 6–8). For this project, the virulent OIE reference strains and neurotropic vaccines were propagated by intracerebral injection of 2-day-old Swiss white mice, and the recent field isolates of AHSV were propagated in either BHK-21 or Vero cells. Extraction and purification of dsRNA, sequence-independent genome amplification, Roche 454 sequencing, and de novo sequence assembly were done as described previously (9).
TABLE 1

History of 27 AHSV isolates from a 76-year period (1933–2009)

AHSV serotypeOriginal isolateIsolate no. or yr of isolationPassage levelaOriginAccession no.
History of the current OIE reference strains of African horse sickness virus used at ARC-OVI
    1HS 61/61bHS 29/62c2SNelspruit, South AfricaKF859986KF859995
    2UnknownHS 82/61c 3SSouth AfricaKF859996KF860005
    3HS 13/63c4SMalmesbury, South AfricaKM886354KM886363
    4HS 47/58 (Specimen 341)HS 32/62c 1SZimbabweKM609465KM609474
    5FR (Fourie)HS 30/62c 2SSouth AfricaKM886344KM886353
    6HS 09/58 (Mule 3858)HS 39/631SKaalplaas, South AfricaKF860006KF860015
    6HS 02/75c4SSouth AfricaKP009741KP009750
    7HS 59/61HS 31/62c2SKaalplaas, South AfricaKF860016KF860025
    8HS 10/62c 2SKenyaKF860026KF860035
    9HS 90/614SChad (Fort Lamy)KF860036KF860045
History of recent field isolates of African horse sickness virus
    1HS 21/07UnknownSouth AfricaKP009621KP009630
    2HS 90/072VeroSouth AfricaKP009631KP009640
    3HS 73/08UnknownSouth AfricaKP009641KP009650
    4HS 128/061VeroSouth AfricaKP009651KP009660
    5HS 28/08UnknownSouth AfricaKP009661KP009670
    6HS 04/08UnknownSouth AfricaKP009671KP009680
    7HS 23/08UnknownSouth AfricaKP009681KP009690
    8HS 29/001S,5BHKSouth AfricaKP009691KP009700
    8HS 83/043Vero,1BHKSouth AfricaKP009721KP009730
    9HS 27/08UnknownSouth AfricaKP009701KP009710
    9HS 72/08UnknownSouth AfricaKP009731KP009740
    9HS145/09UnknownSouth AfricaKP033466KP033475
History of the historic neurotropic strains of African horse sickness virus
    111801933100+ in adult miceSouth AfricaKP009711KP009720
    3L1940100+ in adult miceLadysmith, South AfricaKP009761KP009770
    4Vryheid1938100+ in adult miceVryheid, South AfricaKP009771KP009780
    5Westerman1936100+ in adult miceSouth AfricaKP009781KP009790
    7Karen1952100+ in adult miceKabete, KenyaKP009751KP009760

The passage level refers to the final passage number before dsRNA extraction and sequencing.

The number after the / indicates the year of the original isolate and the number before the / indicates the number of the isolate during the particular year.

Virulent strains used to develop attenuated vaccines by serial passage in BHK-21 and selection of genetically stable large plaques on Vero cells (6, 7).

History of 27 AHSV isolates from a 76-year period (1933–2009) The passage level refers to the final passage number before dsRNA extraction and sequencing. The number after the / indicates the year of the original isolate and the number before the / indicates the number of the isolate during the particular year. Virulent strains used to develop attenuated vaccines by serial passage in BHK-21 and selection of genetically stable large plaques on Vero cells (6, 7). Here we announce the first complete consensus genome sequence of each of the nine original pathogenic OIE reference strains of AHSV prior to the adaptation of the viruses to cell culture (10), some of the neurotropic AHSV vaccine strains (4, 11), and recent isolates of all nine AHSV serotypes made at the ARC-OVI from 1998 to 2009 (Table 1). In all, we sequenced 10 OIE reference strains (including HS2/75 used for attenuation of AHSV6), 5 neurotropic historic vaccine strains, and 12 recent field isolates. This sequence data set of 27 AHSV strains is the first representing all nine AHSV serotypes from both historical and recent isolates collected over a long period of 76 years (1933 to 2009). These genome sequence sets should be useful for comparison with sequences from live vaccine strains that were derived from them and published sequences from cloned genome segments that are mostly incorrect due to cloning biases, such as the genome segment 2 (VP2) sequence set of all nine AHSV serotypes (12). The consensus genome sequence data set of this announcement has already allowed the development of group- and serotype-specific real-time RT-PCRs (13) and, more importantly, has been used to rescue AHSVs of all nine serotypes by reverse genetics, which verifies their correctness (14).

Nucleotide sequence accession numbers.

The nucleotide sequences have been deposited in GenBank under the accession numbers listed in Table 1.
  8 in total

1.  CULTIVATION OF HORSESICKNESS VIRUS IN TISSUE CULTURE.

Authors:  B J ERASMUS
Journal:  Nature       Date:  1963-11-16       Impact factor: 49.962

2.  History of Orbivirus research in South Africa.

Authors:  Daniel W Verwoerd
Journal:  J S Afr Vet Assoc       Date:  2012-11-13       Impact factor: 1.474

3.  The attenuation of viscerotropic horsesickness virus in tissue culture.

Authors:  B J Erasmus
Journal:  Bull Off Int Epizoot       Date:  1965-05

4.  Improved strategies for sequence-independent amplification and sequencing of viral double-stranded RNA genomes.

Authors:  A C Potgieter; N A Page; J Liebenberg; I M Wright; O Landt; A A van Dijk
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

5.  A first full outer capsid protein sequence data-set in the Orbivirus genus (family Reoviridae): cloning, sequencing, expression and analysis of a complete set of full-length outer capsid VP2 genes of the nine African horsesickness virus serotypes.

Authors:  A C Potgieter; M Cloete; P J Pretorius; A A van Dijk
Journal:  J Gen Virol       Date:  2003-05       Impact factor: 3.891

6.  Evidence for a new field Culicoides vector of African horse sickness in South Africa.

Authors:  R Meiswinkel; J T Paweska
Journal:  Prev Vet Med       Date:  2003-08-28       Impact factor: 2.670

7.  VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.

Authors:  Sandra G P van de Water; René G P van Gennip; Christiaan A Potgieter; Isabel M Wright; Piet A van Rijn
Journal:  J Virol       Date:  2015-06-10       Impact factor: 5.103

8.  Real time RT-PCR assays for detection and typing of African horse sickness virus.

Authors:  Katarzyna Bachanek-Bankowska; Sushila Maan; Javier Castillo-Olivares; Nicola M Manning; Narender Singh Maan; Abraham C Potgieter; Antonello Di Nardo; Geoff Sutton; Carrie Batten; Peter P C Mertens
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

  8 in total
  4 in total

1.  A correlation between capsid protein VP2 and the plaque morphology of African horse sickness virus in cell culture.

Authors:  Mathilde L Schade-Weskott; Antoinette van Schalkwyk; J J O Koekemoer
Journal:  Virus Genes       Date:  2018-05-05       Impact factor: 2.332

2.  Evidence of Intragenic Recombination in African Horse Sickness Virus.

Authors:  Harry G Ngoveni; Antoinette van Schalkwyk; J J Otto Koekemoer
Journal:  Viruses       Date:  2019-07-18       Impact factor: 5.048

3.  African Horse Sickness Caused by Genome Reassortment and Reversion to Virulence of Live, Attenuated Vaccine Viruses, South Africa, 2004-2014.

Authors:  Camilla T Weyer; John D Grewar; Phillippa Burger; Esthea Rossouw; Carina Lourens; Christopher Joone; Misha le Grange; Peter Coetzee; Estelle Venter; Darren P Martin; N James MacLachlan; Alan J Guthrie
Journal:  Emerg Infect Dis       Date:  2016-12-15       Impact factor: 6.883

4.  African Horse Sickness Virus Serotype 1 on Horse Farm, Thailand, 2020.

Authors:  Napawan Bunpapong; Kamonpan Charoenkul; Chanakarn Nasamran; Ekkapat Chamsai; Kitikhun Udom; Supanat Boonyapisitsopa; Rachod Tantilertcharoen; Sawang Kesdangsakonwut; Navapon Techakriengkrai; Sanipa Suradhat; Roongroje Thanawongnuwech; Alongkorn Amonsin
Journal:  Emerg Infect Dis       Date:  2021-08       Impact factor: 6.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.